Abstract
We present the utility of a plan evaluation tool for a multi-course radiation treatment consisting of a highly heterogeneous SFRT plan followed by a course of curative radiation therapy for large and bulky unresectable tumors. For a more accurate plan assessment, this novel method calculates the voxelized biological effective dose (BED) spatially from each course and combines them into a single spatial BED distribution (s-BED). Ten previously treated head and neck (H&N) cancer patients with MLC-based 3D-conformal SFRT (15 Gy in 1 fraction) followed by a curative course of VMAT for 66–70 Gy in 33–35 fractions were retrospectively analyzed using this new s-BED method. The s-BED calculations were based on the standard linear-quadratic (LQ) model. Evaluations of mean BED using this s-BED method were compared to other methodologies that use each course's DVH, mean dose, and prescription dose. From this, tumor control probability (TCP) was calculated using these different methodologies. Lastly, doses to nearby organs at risk (OARs) were evaluated using the s-BED method and compared to each course's physical dose distribution. The OARs evaluated were the spinal cord, brainstem, optic pathway, cochlea, parotid glands, larynx, esophagus, and mandible. From the physical dose distributions, a s-BED distribution and a spatial EQD2 (s-EQD2) distribution were able to be calculated and visualized. The various methods of calculating mean BED using each course's dose prescription, mean dose, DVH, and from the s-BED resulted in varying mean BED: 121.8 Gy, 99.7 Gy, 88.3 Gy, and 100.6 Gy, respectively. In turn, this also gave varying predictions in tumor response: 100.0%, 98.2%, 92.3%, and 91.1%, respectively. Of the 8 H&N patients who received follow-up imaging, 7 (87.5%) had local tumor control. Reported toxicities of this cohort saw 2 cases of grade 3 toxicities (skin desquamation), 3 grade 1 toxicities (oral mucositis and odynophagia), and 1 grade 4 toxicity (necrotizing fasciitis). The composite s-BED distributions provided a means of better understanding the effective biological dose being delivered to both the target and nearby OARs spatially. Future utilization of this method during the treatment planning process may allow for more personalized treatment prescriptions for the SFRT course and the follow-up combination therapy, potentially enhancing therapeutic benefits in managing large and bulky unresectable tumors.
| Original language | English |
|---|---|
| Pages (from-to) | 237-243 |
| Number of pages | 7 |
| Journal | Medical Dosimetry |
| Volume | 50 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 1 2025 |
Bibliographical note
Publisher Copyright:© 2025 American Association of Medical Dosimetrists
Funding
This research was supported by pilot funding provided by the Support from the University of Kentucky Markey Cancer Center's Cancer Center Support Grant (P30 CA177558) and the Department of Radiation Medicine, which enabled services from the Biostatistics Shared Resource Facility/Facilities, whose services were used in the conduct of this research.
| Funders | Funder number |
|---|---|
| Department of Radiation Medicine | |
| University of Kentucky Markey Comprehensive Cancer Center | P30 CA177558 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Combination therapy
- Indirect cell kill
- Large and bulky tumors
- SFRT
- Spatial BED
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
- Oncology
- Radiology Nuclear Medicine and imaging
Fingerprint
Dive into the research topics of 'Plan evaluation tool for spatially fractionated radiation therapy for unresectable large tumors via spatial biological effective dose modeling in combination therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver